The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; ##STR00001## or a pharmaceutically acceptable salt, solvate or prodrug thereof.

The Governing Council of the University of Toronto

UTI Limited Partnership

Indiana University Research and Technology Corporation

Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof. ##STR00001##

The present disclosure provides methods for obtaining gaultherin, a natural salicylate derivative, from plant tissue. The methods involve preventing the hydrolysis of the gaultherin in the plant tissue by disrupting the plant tissue under solvent conditions lacking a drying agent. The disclosure further provides various forms of plant-derived gaultherin, including alcoholic extracts, aqueous solutions and dried preparations, all suitable for use as a natural aspirin substitute. Moreover, the disclosure provides methods of using gaultherin-containing compositions to increase serum salicylic acid, to treat cancer cells, to treat cardiovascular (e.g., cardiopulmonary) conditions, to treat anti-inflammatory responses, and to inhibit cyclooxygenase.

Rutgers University, The State University of New Jersey

Methods of administering gaultherin-containing compositions

This disclosure relates to novel compounds containing an H.sub.2S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a H.sub.2S-releasing moiety alone (HS-NSAIDs) and NSAID containing a NO-releasing moiety alone (NO-NSAIDs). The compounds, in addition, exhibit reduced side effect, e.g., reduced stomach ulcers, upon administration.

salicylic acid/kræft

Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Methods of administering gaultherin-containing compositions

No- and H.sub.2S-releasing compounds

Den mest komplette database med medicinske urter understøttet af videnskab